CVE-2012-1674 in Siebel Clinical
Summary
by MITRE
Unspecified vulnerability in the Siebel Clinical component in Oracle Industry Applications 7.7, 7.8, 8.0.0.x, 8.1.1.x, and 8.2.2.x allows remote authenticated users to affect integrity via unknown vectors related to Web UI.
Be aware that VulDB is the high quality source for vulnerability data.
Analysis
by VulDB Data Team • 05/05/2017
The vulnerability identified as CVE-2012-1674 resides within the Siebel Clinical component of Oracle Industry Applications, affecting versions 7.7 through 8.2.2.x. This represents a significant security weakness in the healthcare industry software suite that was widely deployed in clinical research environments. The affected component is part of Oracle's broader industry applications portfolio, specifically designed for managing clinical trial data and research processes. The vulnerability's classification as unspecified indicates that the exact technical details were not fully disclosed in the initial vulnerability report, though the impact on data integrity is clearly documented.
The technical flaw manifests through unknown vectors related to the Web UI component of the Siebel Clinical system, suggesting that the vulnerability exists within the user interface layer that handles web-based interactions. This web-based attack surface typically involves HTTP request processing, form handling, and session management components that could be exploited by authenticated users. The fact that this is a remote vulnerability means that attackers do not need physical access to the system, and the authenticated requirement indicates that the threat actor must already have valid credentials to the system. This creates a particularly dangerous scenario where compromised accounts could be leveraged to manipulate critical clinical data, potentially affecting patient safety and regulatory compliance.
The operational impact of this vulnerability extends beyond simple data corruption, as it directly threatens the integrity of clinical research data that is critical for regulatory submissions and patient care decisions. In healthcare environments, maintaining data integrity is paramount for compliance with regulations such as HIPAA and FDA guidelines, making this vulnerability particularly concerning for organizations that rely on Siebel Clinical for their research operations. The potential for data manipulation could lead to invalid clinical trial results, compromised patient records, and regulatory violations that could result in significant financial penalties and legal consequences. Organizations using these specific versions of Oracle Industry Applications face a heightened risk of data integrity breaches that could undermine their entire research and development processes.
Mitigation strategies for this vulnerability should focus on immediate patch management and access control reinforcement. Organizations must prioritize applying the relevant Oracle security patches that address this specific flaw, though the unspecified nature of the vulnerability may require careful testing before deployment. Network segmentation and privileged access controls should be implemented to limit the potential impact if the vulnerability is exploited. The vulnerability aligns with CWE-20 (Improper Input Validation) and CWE-264 (Permissions, Privileges, and Access Controls) categories, and could potentially map to ATT&CK techniques involving privilege escalation and data manipulation. Regular security assessments and monitoring of web application traffic should be implemented to detect any suspicious activities that might indicate exploitation attempts, while maintaining comprehensive audit trails of all user activities within the Siebel Clinical environment.